Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    350 Collins Street
    Suite 4, Level 14
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity

Ongoing rate hikes have investors spooked.
stocks

ASX dividend champions: Stocks, ETFs and LICs

Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks

SpaceX’s IPO filing: Big spending, big losses

The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,840.809.50-0.11%
CAC 408,149.3431.920.39%
DAX 4024,879.17141.930.57%
Dow JONES (US)50,009.35645.471.31%
FTSE 10010,439.697.350.07%
HKSE25,386.52264.60-1.03%
NASDAQ26,270.36399.651.54%
Nikkei 22561,684.141,879.733.14%
NZX 50 Index12,878.07117.040.92%
S&P 5007,432.9779.361.08%
S&P/ASX 2008,621.706.30-0.07%
SSE Composite Index4,077.2884.91-2.04%

Market Movers